From the Journals

Triple-therapy cuts COPD exacerbations

The combination of an inhaled long-acting beta2-agonist, long-acting muscarinic antagonist, and glucocorticoid may reduce moderate to severe...


News from the FDA/CDC

FDA approves starting dose of roflumilast

Taking a smaller dose of a drug currently used to treat COPD may prevent patients from discontinuing their use of the larger therapeutic dose.

News from the FDA/CDC

Nebulized LAMA for COPD approved

A long-acting muscarinic antagonist for COPD is now available in a nebulizer form in the United States.